Cargando…
Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR
Introduction: In-vivo quantification of the serotonin transporter (SERT) guided our understanding of many neuropsychiatric disorders. A recently introduced bolus plus constant infusion protocol has been shown to allow the reliable determination of SERT binding with reduced scan time. In this work, t...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639732/ https://www.ncbi.nlm.nih.gov/pubmed/31354428 http://dx.doi.org/10.3389/fnmol.2019.00172 |
_version_ | 1783436519753646080 |
---|---|
author | Silberbauer, Leo R. Gryglewski, Gregor Berroterán-Infante, Neydher Rischka, Lucas Vanicek, Thomas Pichler, Verena Hienert, Marius Kautzky, Alexander Philippe, Cecile Godbersen, Godber M. Vraka, Chrysoula James, Gregory M. Wadsak, Wolfgang Mitterhauser, Markus Hacker, Marcus Kasper, Siegfried Hahn, Andreas Lanzenberger, Rupert |
author_facet | Silberbauer, Leo R. Gryglewski, Gregor Berroterán-Infante, Neydher Rischka, Lucas Vanicek, Thomas Pichler, Verena Hienert, Marius Kautzky, Alexander Philippe, Cecile Godbersen, Godber M. Vraka, Chrysoula James, Gregory M. Wadsak, Wolfgang Mitterhauser, Markus Hacker, Marcus Kasper, Siegfried Hahn, Andreas Lanzenberger, Rupert |
author_sort | Silberbauer, Leo R. |
collection | PubMed |
description | Introduction: In-vivo quantification of the serotonin transporter (SERT) guided our understanding of many neuropsychiatric disorders. A recently introduced bolus plus constant infusion protocol has been shown to allow the reliable determination of SERT binding with reduced scan time. In this work, the outcomes of two methods, a bolus injection paradigm on a GE PET camera, and a bolus plus infusion paradigm on a combined Siemens PET/MR camera were compared. Methods: A total of seven healthy subjects underwent paired PET and paired PET/MR scans each with intravenous double-blind application of 7.5 mg citalopram or saline in a randomized cross-over study design. While PET scans were performed according to standard protocols and non-displaceable binding potentials (BP(ND)) were calculated using the multi-linear reference tissue model, during PET/MR measurements [(11)C]DASB was applied as bolus plus constant infusion, and BP(ND) was calculated using the steady state method and data acquired at tracer equilibrium. Occupancies were calculated as the relative decrease in BP(ND) between saline and citalopram scans. Results: During placebo scans, a mean difference in BP(ND) of −0.08 (−11.71%) across all ROIs was found between methods. PET/MR scans resulted in higher BP(ND) estimates than PET scans in all ROIs except the midbrain. A mean difference of −0.19 (−109.40%) across all ROIs between methods was observed for citalopram scans. PET/MR scans resulted in higher BP(ND) estimates than PET scans in all ROIs. For occupancy, a mean difference of 23.12% (21.91%) was observed across all ROIs. PET/MR scans resulted in lower occupancy compared to PET scans in all ROIs except the temporal cortex. While for placebo, BP(ND) of high-binding regions (thalamus and striatum) exhibited moderate reliability (ICC = 0.66), during citalopram scans ICC decreased (0.36–0.46). However, reliability for occupancy remained high (0.57–0.82). Conclusion: Here, we demonstrated the feasibility of reliable and non-invasive SERT quantification using a [(11)C]DASB bolus plus constant infusion protocol at a hybrid PET/MR scanner, which might facilitate future pharmacological imaging studies. Highest agreement with established methods for quantification of occupancy and SERT BP(ND) at baseline was observed in subcortical high-binding regions. |
format | Online Article Text |
id | pubmed-6639732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66397322019-07-26 Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR Silberbauer, Leo R. Gryglewski, Gregor Berroterán-Infante, Neydher Rischka, Lucas Vanicek, Thomas Pichler, Verena Hienert, Marius Kautzky, Alexander Philippe, Cecile Godbersen, Godber M. Vraka, Chrysoula James, Gregory M. Wadsak, Wolfgang Mitterhauser, Markus Hacker, Marcus Kasper, Siegfried Hahn, Andreas Lanzenberger, Rupert Front Mol Neurosci Neuroscience Introduction: In-vivo quantification of the serotonin transporter (SERT) guided our understanding of many neuropsychiatric disorders. A recently introduced bolus plus constant infusion protocol has been shown to allow the reliable determination of SERT binding with reduced scan time. In this work, the outcomes of two methods, a bolus injection paradigm on a GE PET camera, and a bolus plus infusion paradigm on a combined Siemens PET/MR camera were compared. Methods: A total of seven healthy subjects underwent paired PET and paired PET/MR scans each with intravenous double-blind application of 7.5 mg citalopram or saline in a randomized cross-over study design. While PET scans were performed according to standard protocols and non-displaceable binding potentials (BP(ND)) were calculated using the multi-linear reference tissue model, during PET/MR measurements [(11)C]DASB was applied as bolus plus constant infusion, and BP(ND) was calculated using the steady state method and data acquired at tracer equilibrium. Occupancies were calculated as the relative decrease in BP(ND) between saline and citalopram scans. Results: During placebo scans, a mean difference in BP(ND) of −0.08 (−11.71%) across all ROIs was found between methods. PET/MR scans resulted in higher BP(ND) estimates than PET scans in all ROIs except the midbrain. A mean difference of −0.19 (−109.40%) across all ROIs between methods was observed for citalopram scans. PET/MR scans resulted in higher BP(ND) estimates than PET scans in all ROIs. For occupancy, a mean difference of 23.12% (21.91%) was observed across all ROIs. PET/MR scans resulted in lower occupancy compared to PET scans in all ROIs except the temporal cortex. While for placebo, BP(ND) of high-binding regions (thalamus and striatum) exhibited moderate reliability (ICC = 0.66), during citalopram scans ICC decreased (0.36–0.46). However, reliability for occupancy remained high (0.57–0.82). Conclusion: Here, we demonstrated the feasibility of reliable and non-invasive SERT quantification using a [(11)C]DASB bolus plus constant infusion protocol at a hybrid PET/MR scanner, which might facilitate future pharmacological imaging studies. Highest agreement with established methods for quantification of occupancy and SERT BP(ND) at baseline was observed in subcortical high-binding regions. Frontiers Media S.A. 2019-07-12 /pmc/articles/PMC6639732/ /pubmed/31354428 http://dx.doi.org/10.3389/fnmol.2019.00172 Text en Copyright © 2019 Silberbauer, Gryglewski, Berroterán-Infante, Rischka, Vanicek, Pichler, Hienert, Kautzky, Philippe, Godbersen, Vraka, James, Wadsak, Mitterhauser, Hacker, Kasper, Hahn and Lanzenberger. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Silberbauer, Leo R. Gryglewski, Gregor Berroterán-Infante, Neydher Rischka, Lucas Vanicek, Thomas Pichler, Verena Hienert, Marius Kautzky, Alexander Philippe, Cecile Godbersen, Godber M. Vraka, Chrysoula James, Gregory M. Wadsak, Wolfgang Mitterhauser, Markus Hacker, Marcus Kasper, Siegfried Hahn, Andreas Lanzenberger, Rupert Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR |
title | Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR |
title_full | Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR |
title_fullStr | Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR |
title_full_unstemmed | Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR |
title_short | Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR |
title_sort | serotonin transporter binding in the human brain after pharmacological challenge measured using pet and pet/mr |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639732/ https://www.ncbi.nlm.nih.gov/pubmed/31354428 http://dx.doi.org/10.3389/fnmol.2019.00172 |
work_keys_str_mv | AT silberbauerleor serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT gryglewskigregor serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT berroteraninfanteneydher serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT rischkalucas serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT vanicekthomas serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT pichlerverena serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT hienertmarius serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT kautzkyalexander serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT philippececile serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT godbersengodberm serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT vrakachrysoula serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT jamesgregorym serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT wadsakwolfgang serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT mitterhausermarkus serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT hackermarcus serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT kaspersiegfried serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT hahnandreas serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr AT lanzenbergerrupert serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr |